Abstract:Purpose/Objective: To date, we have treated approximately 800 patients with IMRT at this institution using the Siemens Primus or Primart linear accelerators and the SMLC delivery technique. Prior to the initial patient treatment, each plan is evaluated and a series of QA tests are performed including absolute dose verification. This verification is a comparison between the dose calculated in phantom by the treatment planning system and the dose measured in phantom during irradiation. Our clinical acceptance criteria dictate that the values should agree to within ± 3% for treatment to begin. Values exceeding this limit trigger additional analysis, measurement and double-checking prior to patient treatment. An example is given where the mean deviation value was −6.5% with a maximum deviation measured of −8.8%. The focus of this work is to analyze the accuracy of our dosimetry QA procedure and address discrepancies that are significantly greater than ± 3%.Materials/Methods: All IMRT treatment plans are generated using the Corvus treatment planning system. Once a satisfactory plan is obtained a hybrid plan is generated. This plan utilizes the leaf sequences and associated MU designed for the patient plan and calculates dose on a virtual phantom. The physical phantom is then irradiated under the same conditions using the same leaf sequences. An absolute dose comparison is made by comparing dose in the physical phantom as measured using a 0.125cc PTW ionization chamber with dose predicted at the same point(s) in the virtual phantom by the treatment planning system. Agreement to within ± 3% indicates that the plan is appropriately deliverable as far as absolute dose is concerned. Values exceeding this limit prompt additional investigation. This investigation includes reassessing the treatment plan and hybrid plan for errors in data extraction, investigation of input data into the R&V system for accuracy and completeness, and investigation of deliverability with respect to beam placement. The phantom irradiation is then repeated to eliminate errors due to improper setup. Discrepancies outside a ± 4% window are verified using Monte Carlo simulations of both the dose in the virtual phantom and dose in the original patient CT data set. With agreement between the original Corvus calculated relative dose distributions and the distributions generated in film and Monte Carlo simulations, the MU can be scaled appropriately to bring the absolute dose into our acceptable range. When agreement is not present the individual patient plans are regenerated with changes in input parameters and/or beam directions.Results: Upon evaluation of our absolute dose data it was found that the agreement between measured dose and dose predicted by the planning system in phantom was within ± 1% for 37.9% of the cases, ± 2% for 68.6% and ± 3% for 93.6% of the cases. The discrepancies were more than 3% and more than 4% in only 6.4% and less than 1% of all cases, respectively. Monte Carlo calculation of absolute dose compares to within 2% of dose in phantom or the patient CT data set in the non-gradient portion of the dose distribution associated with the target as tested for 20 prostate cases.Conclusions: There appear to be some intensity maps that are not deliverable to within our clinical acceptance criteria even though the planning system generated a leaf sequence and associated MU set. Verification of absolute dose as well as the relative dose distribution is essential especially in these cases. While MU scaling may result in acceptable delivery, verification of the resultant dose distribution is needed since the Siemens linacs allow for integer MU delivery only. Monte Carlo can serve as an independent dose verification tool in the QA process. Evaluation of different leaf sequencing options is made for these cases and comparisons made using both measurement and Monte Carlo simulations. Purpose/Objective: To date, we have treated approximately 800 patients with IMRT at this institution using the Siemens Primus or Primart linear accelerators and the SMLC delivery technique. Prior to the initial patient treatment, each plan is evaluated and a series of QA tests are performed including absolute dose verification. This verification is a comparison between the dose calculated in phantom by the treatment planning system and the dose measured in phantom during irradiation. Our clinical acceptance criteria dictate that the values should agree to within ± 3% for treatment to begin. Values exceeding this limit trigger additional analysis, measurement and double-checking prior to patient treatment. An example is given where the mean deviation value was −6.5% with a maximum deviation measured of −8.8%. The focus of this work is to analyze the accuracy of our dosimetry QA procedure and address discrepancies that are significantly greater than ± 3%. Materials/Methods: All IMRT treatment plans are generated using the Corvus treatment planning system. Once a satisfactory plan is obtained a hybrid plan is generated. This plan utilizes the leaf sequences and associated MU designed for the patient plan and calculates dose on a virtual phantom. The physical phantom is then irradiated under the same conditions using the same leaf sequences. An absolute dose comparison is made by comparing dose in the physical phantom as measured using a 0.125cc PTW ionization chamber with dose predicted at the same point(s) in the virtual phantom by the treatment planning system. Agreement to within ± 3% indicates that the plan is appropriately deliverable as far as absolute dose is concerned. Values exceeding this limit prompt additional investigation. This investigation includes reassessing the treatment plan and hybrid plan for errors in data extraction, investigation of input data into the R&V system for accuracy and completeness, and investigation of deliverability with respect to beam placement. The phantom irradiation is then repeated to eliminate errors due to improper setup. Discrepancies outside a ± 4% window are verified using Monte Carlo simulations of both the dose in the virtual phantom and dose in the original patient CT data set. With agreement between the original Corvus calculated relative dose distributions and the distributions generated in film and Monte Carlo simulations, the MU can be scaled appropriately to bring the absolute dose into our acceptable range. When agreement is not present the individual patient plans are regenerated with changes in input parameters and/or beam directions. Results: Upon evaluation of our absolute dose data it was found that the agreement between measured dose and dose predicted by the planning system in phantom was within ± 1% for 37.9% of the cases, ± 2% for 68.6% and ± 3% for 93.6% of the cases. The discrepancies were more than 3% and more than 4% in only 6.4% and less than 1% of all cases, respectively. Monte Carlo calculation of absolute dose compares to within 2% of dose in phantom or the patient CT data set in the non-gradient portion of the dose distribution associated with the target as tested for 20 prostate cases. Conclusions: There appear to be some intensity maps that are not deliverable to within our clinical acceptance criteria even though the planning system generated a leaf sequence and associated MU set. Verification of absolute dose as well as the relative dose distribution is essential especially in these cases. While MU scaling may result in acceptable delivery, verification of the resultant dose distribution is needed since the Siemens linacs allow for integer MU delivery only. Monte Carlo can serve as an independent dose verification tool in the QA process. Evaluation of different leaf sequencing options is made for these cases and comparisons made using both measurement and Monte Carlo simulations.

Stability analysis of Octavius 4D system

Analysis of 2 010 patient-specific intensity-modulated radiation therapy dosimetric verification results

Dose delivery uncertainties assessment in the field junction region of craniospinal irradiation with Volumetric Modulated Arc Therapy using a robustness index and experimental dose verification

Commissioning of Axesse Accelerator for Volumetric Modulated Arc Therapy

Evaluation of the Stability of Dosimetric Parameters of Mobetron

Influence of dose calculation algorithms on the helical diode array using volumetric‐modulated arc therapy for small targets

Evaluation research of implementing intensity-modulated verification of individualization for patient based on various dosimetric tools

Empirical Model for a Three-Dimensional Dose Verification System and Its Application in Volumetric-Modulated Arc Therapy for Heterogeneous and Long-Target Tumors

Analysis on the delivery quality assurance using SunCHECK for the VMAT in halcyon linear accelerator

Analysis of the Medical Linear Accelerator Output Stability

Evaluation of patient-specific quality assurance for fractionated stereotactic treatment plans with 6 and 10MV photon beams in beam-matched linacs

Monte Carlo modeling of HD120 multileaf collimator on Varian TrueBeam linear accelerator for verification of 6X and 6X FFF VMAT SABR treatment plans

A method for selecting reference beam model of VMAT plans with three 6MV beam-matched linear accelerators during radiation oncology

A Comparative Study of Dosimetric Verification of Halcyon™ Treatment Plans Using Varian Portal Dosimetry and PTW Array 1500

IMRT QA Analysis: What to Do with Unresolved Discrepancies?

Research on verifications of physical parameters of virtual wedge on Siemens accelerator by Mapcheck

Development of 3D Dosimetry System Using Polymer Gel (TENOMAG) and Optical-CT Scanner in Prostate IMRT

Investigation of a 3D dosimetry system utilizing radio-chromic gel and telecentric optical-CT readout

Halcyon Clinical Performance Evaluation: A Log File-Based Study in Comparison with a C-arm Linac.

SU-GG-T-250: 3D Dose Reconstruction for Delivery Quality Assurance (DQA) from Multiple 2D Planes Using the OCTAVIOUS Phantom

Comparative assessment and QA measurement array validation of Monte Carlo and Collapsed Cone dose algorithms for small fields and clinical treatment plans